

**Table 3.4**  
**Verified Outcomes (Annualized Percentages) by Age at Enrollment for SRC Super Cohort Participants<sup>1</sup>**

Data as of: March 1, 2019; Events through September 30, 2010 and March 1, 2019

	Age at Enrollment				
	Total	50-54	55-59	60-69	70-79
<b>Outcomes through Extension Study 2005-2010</b>					
<b>Number randomized</b>	117634	14781	22638	53171	27044
<b>Mean follow-up (months)</b>	142.7	154.9	151.9	142.9	128.1
<b>Cardiovascular<sup>2</sup></b>					
CHD <sup>3</sup>	5434 (0.39%)	201 (0.11%)	489 (0.17%)	2362 (0.37%)	2382 (0.83%)
CHD death <sup>4</sup>	1891 (0.14%)	49 (0.03%)	104 (0.04%)	693 (0.11%)	1045 (0.36%)
Clinical MI	4044 (0.29%)	159 (0.08%)	398 (0.14%)	1834 (0.29%)	1653 (0.57%)
Angina <sup>5</sup>	3623 (0.38%)	139 (0.11%)	423 (0.22%)	1749 (0.41%)	1312 (0.63%)
CABG/PTCA	6113 (0.44%)	241 (0.13%)	711 (0.25%)	3161 (0.50%)	2000 (0.69%)
Carotid artery disease	1111 (0.08%)	48 (0.03%)	117 (0.04%)	520 (0.08%)	426 (0.15%)
Congestive heart failure, WHI <sup>5</sup>	2797 (0.29%)	78 (0.06%)	201 (0.11%)	1096 (0.26%)	1422 (0.68%)
Stroke	4255 (0.30%)	124 (0.06%)	319 (0.11%)	1856 (0.29%)	1956 (0.68%)
PVD	984 (0.07%)	24 (0.01%)	88 (0.03%)	460 (0.07%)	412 (0.14%)
Coronary disease <sup>6</sup>	11771 (0.84%)	455 (0.24%)	1244 (0.43%)	5456 (0.86%)	4616 (1.60%)
<b>Total cardiovascular disease</b>	16773 (1.20%)	626 (0.33%)	1662 (0.58%)	7667 (1.21%)	6818 (2.36%)
<b>Fractures<sup>2</sup></b>					
Hip fracture	2955 (0.21%)	63 (0.03%)	186 (0.06%)	1108 (0.18%)	1598 (0.55%)
<b>Outcomes through Extension Study 2010-2020</b>					
<b>Number randomized</b>	117634	14781	22638	53171	27044
<b>Mean follow-up (months)</b>	193.4	221.4	216.1	194.9	156.0
<b>Cancer</b>					
Breast cancer	10445 (0.55%)	1379 (0.51%)	2230 (0.55%)	4853 (0.56%)	1983 (0.56%)
Invasive breast cancer	8738 (0.46%)	1103 (0.40%)	1856 (0.46%)	4079 (0.47%)	1700 (0.48%)
In situ breast cancer	1859 (0.10%)	300 (0.11%)	405 (0.10%)	849 (0.10%)	305 (0.09%)
Ovarian cancer	1001 (0.05%)	121 (0.04%)	192 (0.05%)	475 (0.05%)	213 (0.06%)
Endometrial cancer <sup>7</sup>	1488 (0.13%)	166 (0.10%)	334 (0.13%)	689 (0.14%)	299 (0.15%)
Colorectal cancer	2382 (0.13%)	136 (0.05%)	310 (0.08%)	1185 (0.14%)	751 (0.21%)
Other cancer <sup>8</sup>	13262 (0.70%)	1252 (0.46%)	2260 (0.55%)	6502 (0.75%)	3248 (0.92%)
<b>Total cancer</b>	26121 (1.38%)	2807 (1.03%)	4884 (1.20%)	12443 (1.44%)	5987 (1.70%)
<b>Deaths</b>					
Cardiovascular deaths	8809 (0.46%)	181 (0.07%)	521 (0.13%)	3544 (0.41%)	4563 (1.30%)
Cancer deaths	9042 (0.48%)	575 (0.21%)	1224 (0.30%)	4441 (0.51%)	2802 (0.80%)
Other known cause	9841 (0.52%)	297 (0.11%)	788 (0.19%)	4419 (0.51%)	4337 (1.23%)
Unknown cause	1794 (0.09%)	63 (0.02%)	188 (0.05%)	938 (0.11%)	605 (0.17%)
<b>Total death<sup>9</sup></b>	43973 (1.99%)	1501 (0.48%)	3656 (0.79%)	19211 (1.92%)	19605 (4.61%)

<sup>1</sup> The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

<sup>2</sup> Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2020. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

<sup>3</sup> "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

<sup>4</sup> "CHD death" includes definite and possible CHD death.

<sup>5</sup> Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

<sup>6</sup> "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

<sup>7</sup> Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>8</sup> Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>9</sup> Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.